| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 55 | 2023 | 22072 | 1.900 |
Why?
|
| Protein-Arginine N-Methyltransferases | 4 | 2021 | 131 | 1.520 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 4 | 2024 | 81 | 1.480 |
Why?
|
| Phosphoric Monoester Hydrolases | 10 | 2004 | 412 | 1.360 |
Why?
|
| Cell Line, Tumor | 79 | 2024 | 16939 | 1.320 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 4 | 2024 | 319 | 1.220 |
Why?
|
| PTEN Phosphohydrolase | 19 | 2015 | 1115 | 1.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 18 | 2023 | 2864 | 1.010 |
Why?
|
| Antineoplastic Agents | 27 | 2021 | 13630 | 1.000 |
Why?
|
| MAP Kinase Signaling System | 8 | 2021 | 1484 | 0.970 |
Why?
|
| Oncogenes | 8 | 2017 | 1220 | 0.950 |
Why?
|
| Cyclin-Dependent Kinase 4 | 5 | 2021 | 556 | 0.950 |
Why?
|
| Proto-Oncogene Proteins | 22 | 2014 | 4490 | 0.940 |
Why?
|
| Xenograft Model Antitumor Assays | 23 | 2020 | 3584 | 0.930 |
Why?
|
| Biotinylation | 1 | 2024 | 184 | 0.900 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 6 | 2018 | 368 | 0.880 |
Why?
|
| Tumor Suppressor Proteins | 14 | 2004 | 2802 | 0.830 |
Why?
|
| Acidaminococcus | 1 | 2022 | 9 | 0.830 |
Why?
|
| Genes, Tumor Suppressor | 10 | 2010 | 1055 | 0.830 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2021 | 12 | 0.810 |
Why?
|
| Aminopyridines | 7 | 2017 | 564 | 0.800 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2021 | 47 | 0.790 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2021 | 71 | 0.780 |
Why?
|
| Genes, Essential | 2 | 2021 | 184 | 0.780 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 2803 | 0.770 |
Why?
|
| Prostatic Neoplasms | 22 | 2024 | 11345 | 0.740 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2020 | 5253 | 0.720 |
Why?
|
| Cell Proliferation | 23 | 2024 | 10446 | 0.700 |
Why?
|
| Ubiquitination | 1 | 2024 | 1008 | 0.650 |
Why?
|
| Ubiquitin | 1 | 2024 | 838 | 0.640 |
Why?
|
| Pyrimidines | 11 | 2018 | 3016 | 0.610 |
Why?
|
| ras Proteins | 5 | 2018 | 1052 | 0.610 |
Why?
|
| Research Personnel | 1 | 2023 | 582 | 0.610 |
Why?
|
| Allosteric Site | 2 | 2017 | 103 | 0.590 |
Why?
|
| Retinoblastoma Protein | 9 | 2005 | 670 | 0.560 |
Why?
|
| Purines | 2 | 2017 | 605 | 0.560 |
Why?
|
| Mice, Nude | 21 | 2021 | 3607 | 0.550 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2017 | 431 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-akt | 19 | 2013 | 2448 | 0.550 |
Why?
|
| Genetic Techniques | 1 | 2019 | 428 | 0.540 |
Why?
|
| Transcription Factors | 24 | 2018 | 12103 | 0.540 |
Why?
|
| DNA-Binding Proteins | 22 | 2018 | 9585 | 0.530 |
Why?
|
| Cyclin-Dependent Kinase 6 | 4 | 2021 | 346 | 0.530 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2016 | 28 | 0.530 |
Why?
|
| Mutation | 40 | 2023 | 29932 | 0.530 |
Why?
|
| Gene Expression Regulation, Neoplastic | 27 | 2020 | 8515 | 0.530 |
Why?
|
| Signal Transduction | 36 | 2021 | 23376 | 0.520 |
Why?
|
| Protein Kinase Inhibitors | 25 | 2023 | 5643 | 0.520 |
Why?
|
| Cell Lineage | 8 | 2018 | 2533 | 0.520 |
Why?
|
| Cell Cycle | 15 | 2017 | 2934 | 0.520 |
Why?
|
| Gene Amplification | 12 | 2016 | 1085 | 0.510 |
Why?
|
| Imidazoles | 2 | 2019 | 1180 | 0.510 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2018 | 2919 | 0.510 |
Why?
|
| RNA Interference | 5 | 2017 | 2846 | 0.510 |
Why?
|
| Gene Dosage | 12 | 2015 | 1218 | 0.500 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2019 | 1347 | 0.490 |
Why?
|
| Proto-Oncogene Proteins B-raf | 10 | 2023 | 2053 | 0.490 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2024 | 1889 | 0.480 |
Why?
|
| Niacinamide | 1 | 2017 | 414 | 0.480 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 17 | 2015 | 3775 | 0.480 |
Why?
|
| Pyrroles | 2 | 2018 | 1137 | 0.470 |
Why?
|
| RNA, Small Interfering | 10 | 2018 | 3442 | 0.460 |
Why?
|
| Methionine | 1 | 2016 | 569 | 0.440 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 4 | 2020 | 224 | 0.430 |
Why?
|
| High-Throughput Screening Assays | 5 | 2016 | 944 | 0.420 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2013 | 93 | 0.420 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 698 | 0.420 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 5 | 2010 | 259 | 0.410 |
Why?
|
| Neoplasm Transplantation | 11 | 2018 | 2014 | 0.410 |
Why?
|
| Mice | 62 | 2024 | 81208 | 0.400 |
Why?
|
| Protein Kinases | 5 | 2008 | 1612 | 0.400 |
Why?
|
| Receptors, Fibroblast Growth Factor | 4 | 2013 | 192 | 0.400 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 685 | 0.400 |
Why?
|
| Genomics | 7 | 2016 | 5794 | 0.380 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 3610 | 0.380 |
Why?
|
| Melanoma | 11 | 2019 | 5697 | 0.370 |
Why?
|
| Humans | 168 | 2024 | 760621 | 0.360 |
Why?
|
| Animals | 82 | 2024 | 167963 | 0.360 |
Why?
|
| Gene Expression Profiling | 22 | 2020 | 9411 | 0.360 |
Why?
|
| Chromosome Aberrations | 5 | 2011 | 1764 | 0.350 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2023 | 1613 | 0.330 |
Why?
|
| Enzyme Activation | 11 | 2021 | 3602 | 0.330 |
Why?
|
| Genome, Human | 7 | 2016 | 4417 | 0.330 |
Why?
|
| Loss of Heterozygosity | 5 | 2008 | 659 | 0.320 |
Why?
|
| Cell Cycle Proteins | 12 | 2005 | 3446 | 0.320 |
Why?
|
| Repressor Proteins | 9 | 2018 | 2981 | 0.310 |
Why?
|
| Colorectal Neoplasms | 4 | 2023 | 6853 | 0.310 |
Why?
|
| Pyrazoles | 4 | 2017 | 1999 | 0.310 |
Why?
|
| Phosphorylation | 20 | 2021 | 8313 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2019 | 567 | 0.290 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 4 | 2014 | 211 | 0.290 |
Why?
|
| Thiazoles | 2 | 2014 | 1511 | 0.290 |
Why?
|
| DNA, Neoplasm | 11 | 2011 | 1745 | 0.290 |
Why?
|
| HEK293 Cells | 6 | 2024 | 4264 | 0.280 |
Why?
|
| Cell Survival | 12 | 2018 | 5797 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 21 | 2016 | 15789 | 0.270 |
Why?
|
| Protein Binding | 18 | 2021 | 9335 | 0.270 |
Why?
|
| Transcription, Genetic | 13 | 2018 | 7593 | 0.270 |
Why?
|
| HCT116 Cells | 5 | 2021 | 402 | 0.270 |
Why?
|
| Apoptosis | 14 | 2018 | 9501 | 0.270 |
Why?
|
| Morpholines | 5 | 2014 | 583 | 0.260 |
Why?
|
| Carrier Proteins | 9 | 2001 | 4938 | 0.260 |
Why?
|
| Benzamides | 8 | 2019 | 1369 | 0.250 |
Why?
|
| Software | 2 | 2019 | 4419 | 0.250 |
Why?
|
| Allosteric Regulation | 5 | 2020 | 426 | 0.250 |
Why?
|
| Quinazolines | 8 | 2015 | 1363 | 0.250 |
Why?
|
| beta Catenin | 4 | 2023 | 1043 | 0.240 |
Why?
|
| Fibroblast Growth Factors | 3 | 2019 | 869 | 0.240 |
Why?
|
| Phosphoproteins | 6 | 2021 | 2440 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 6 | 2023 | 642 | 0.240 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2015 | 59 | 0.240 |
Why?
|
| Bacillus Phages | 1 | 2004 | 12 | 0.240 |
Why?
|
| Histones | 3 | 2021 | 2583 | 0.220 |
Why?
|
| MAP Kinase Kinase Kinases | 4 | 2018 | 256 | 0.220 |
Why?
|
| Epithelial Cells | 7 | 2016 | 3663 | 0.220 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2024 | 307 | 0.220 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 2221 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 7 | 2015 | 6068 | 0.220 |
Why?
|
| Staurosporine | 1 | 2004 | 242 | 0.220 |
Why?
|
| Cell Line | 17 | 2013 | 15620 | 0.220 |
Why?
|
| Alleles | 7 | 2010 | 6898 | 0.220 |
Why?
|
| TOR Serine-Threonine Kinases | 6 | 2016 | 2058 | 0.210 |
Why?
|
| Proteins | 4 | 2004 | 6029 | 0.210 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2018 | 717 | 0.210 |
Why?
|
| Drug Discovery | 2 | 2021 | 1057 | 0.200 |
Why?
|
| Receptors, Androgen | 4 | 2016 | 1077 | 0.200 |
Why?
|
| Mutation, Missense | 7 | 2011 | 2566 | 0.200 |
Why?
|
| Cell Division | 7 | 2009 | 4463 | 0.200 |
Why?
|
| Protein Structure, Tertiary | 12 | 2016 | 3800 | 0.200 |
Why?
|
| Substrate Specificity | 4 | 2024 | 1792 | 0.200 |
Why?
|
| Kynurenine | 2 | 2019 | 139 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 5251 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 13 | 2020 | 6131 | 0.190 |
Why?
|
| bcl-X Protein | 3 | 2018 | 413 | 0.190 |
Why?
|
| Transcriptional Activation | 5 | 2002 | 1755 | 0.190 |
Why?
|
| Activin Receptors, Type II | 1 | 2001 | 124 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2017 | 2828 | 0.190 |
Why?
|
| Methylation | 2 | 2021 | 1082 | 0.180 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2004 | 491 | 0.180 |
Why?
|
| Spliceosomes | 1 | 2021 | 129 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2018 | 727 | 0.180 |
Why?
|
| Genes, Retinoblastoma | 2 | 1997 | 125 | 0.180 |
Why?
|
| Gene Knockout Techniques | 2 | 2021 | 802 | 0.170 |
Why?
|
| Gene Library | 4 | 2017 | 1060 | 0.170 |
Why?
|
| Rhabdoid Tumor | 2 | 2013 | 210 | 0.170 |
Why?
|
| Lung Neoplasms | 13 | 2023 | 13262 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2019 | 17 | 0.170 |
Why?
|
| RNA, Messenger | 6 | 2009 | 12766 | 0.170 |
Why?
|
| Gene Knockdown Techniques | 4 | 2019 | 1617 | 0.170 |
Why?
|
| Streptococcus pyogenes | 1 | 2022 | 294 | 0.170 |
Why?
|
| Rats | 10 | 2020 | 23711 | 0.170 |
Why?
|
| Pyridazines | 1 | 2021 | 200 | 0.170 |
Why?
|
| Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor | 1 | 2019 | 11 | 0.170 |
Why?
|
| Nuclear Proteins | 8 | 2021 | 5791 | 0.170 |
Why?
|
| Phenylurea Compounds | 2 | 2013 | 529 | 0.170 |
Why?
|
| raf Kinases | 2 | 2018 | 118 | 0.160 |
Why?
|
| Asparagine | 1 | 2019 | 119 | 0.160 |
Why?
|
| Protein Conformation | 6 | 2016 | 3969 | 0.160 |
Why?
|
| Pyrazines | 2 | 2016 | 1199 | 0.160 |
Why?
|
| Piperidines | 3 | 2016 | 1650 | 0.160 |
Why?
|
| Stomach Neoplasms | 3 | 2019 | 1423 | 0.160 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2016 | 465 | 0.160 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 5 | 2016 | 616 | 0.160 |
Why?
|
| Models, Molecular | 11 | 2021 | 5434 | 0.160 |
Why?
|
| Cell Death | 3 | 2015 | 1672 | 0.160 |
Why?
|
| Prostate | 6 | 2016 | 1793 | 0.160 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2018 | 11 | 0.160 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 562 | 0.150 |
Why?
|
| GTP Phosphohydrolases | 1 | 2021 | 518 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2018 | 358 | 0.150 |
Why?
|
| Retinoblastoma | 2 | 1998 | 317 | 0.150 |
Why?
|
| Molecular Sequence Data | 18 | 2015 | 17624 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2021 | 2873 | 0.150 |
Why?
|
| G1 Phase | 6 | 2006 | 403 | 0.150 |
Why?
|
| Asparaginase | 1 | 2019 | 240 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2021 | 504 | 0.150 |
Why?
|
| Models, Biological | 9 | 2015 | 9467 | 0.150 |
Why?
|
| Protein Array Analysis | 1 | 2019 | 401 | 0.140 |
Why?
|
| Liver Neoplasms | 4 | 2019 | 4319 | 0.140 |
Why?
|
| DNA Methylation | 3 | 2019 | 4373 | 0.140 |
Why?
|
| Epistasis, Genetic | 1 | 2019 | 350 | 0.140 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2013 | 727 | 0.140 |
Why?
|
| Triazines | 1 | 2019 | 310 | 0.140 |
Why?
|
| Gene Deletion | 5 | 2016 | 2668 | 0.140 |
Why?
|
| Receptor, erbB-2 | 4 | 2013 | 2554 | 0.140 |
Why?
|
| Kidney Neoplasms | 4 | 2019 | 4312 | 0.140 |
Why?
|
| Cytoplasm | 1 | 2021 | 1516 | 0.140 |
Why?
|
| Ion Channels | 1 | 2021 | 1043 | 0.140 |
Why?
|
| Thionucleosides | 1 | 2016 | 13 | 0.140 |
Why?
|
| Deoxyadenosines | 1 | 2016 | 27 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2018 | 1636 | 0.130 |
Why?
|
| Janus Kinase 2 | 3 | 2015 | 542 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 6544 | 0.130 |
Why?
|
| Genes, ras | 5 | 2012 | 655 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 877 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2015 | 380 | 0.130 |
Why?
|
| Genome | 3 | 2016 | 1739 | 0.130 |
Why?
|
| Base Sequence | 16 | 2016 | 12446 | 0.130 |
Why?
|
| Retinal Neoplasms | 1 | 1997 | 146 | 0.130 |
Why?
|
| Genes, erbB-1 | 3 | 2005 | 160 | 0.130 |
Why?
|
| Blotting, Western | 10 | 2014 | 5039 | 0.130 |
Why?
|
| E2F Transcription Factors | 9 | 2005 | 269 | 0.130 |
Why?
|
| Caspases | 2 | 2014 | 878 | 0.120 |
Why?
|
| Multiprotein Complexes | 3 | 2017 | 1120 | 0.120 |
Why?
|
| Diphenylamine | 3 | 2010 | 49 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2021 | 2895 | 0.120 |
Why?
|
| Immunoblotting | 5 | 2013 | 1649 | 0.120 |
Why?
|
| Cell Differentiation | 10 | 2016 | 11481 | 0.120 |
Why?
|
| Disease Models, Animal | 8 | 2017 | 18137 | 0.120 |
Why?
|
| Trans-Activators | 7 | 2005 | 2860 | 0.120 |
Why?
|
| Prostatectomy | 1 | 2003 | 1956 | 0.120 |
Why?
|
| Catalytic Domain | 1 | 2017 | 706 | 0.120 |
Why?
|
| Tankyrases | 1 | 2014 | 13 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2021 | 423 | 0.120 |
Why?
|
| Disease Progression | 4 | 2024 | 13502 | 0.120 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 8 | 1998 | 138 | 0.120 |
Why?
|
| Research | 1 | 2023 | 1974 | 0.120 |
Why?
|
| Chromosome Deletion | 4 | 2008 | 1387 | 0.120 |
Why?
|
| Breast Neoplasms | 8 | 2021 | 21025 | 0.120 |
Why?
|
| RNA Splicing | 1 | 2019 | 915 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 8 | 2013 | 5785 | 0.120 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2013 | 123 | 0.120 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 652 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 895 | 0.120 |
Why?
|
| Adenovirus E1A Proteins | 3 | 2005 | 73 | 0.120 |
Why?
|
| Malformations of Cortical Development | 1 | 2016 | 177 | 0.120 |
Why?
|
| Membrane Proteins | 4 | 2021 | 7850 | 0.120 |
Why?
|
| Genetic Vectors | 3 | 2017 | 3380 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2021 | 1974 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2005 | 315 | 0.110 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2015 | 132 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 5 | 2015 | 5351 | 0.110 |
Why?
|
| Carcinoma | 3 | 2015 | 2331 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2016 | 1596 | 0.110 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 1462 | 0.110 |
Why?
|
| Mice, SCID | 7 | 2014 | 2627 | 0.110 |
Why?
|
| Cadherins | 2 | 2017 | 898 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 8 | 2013 | 4713 | 0.110 |
Why?
|
| Isoquinolines | 1 | 2015 | 353 | 0.110 |
Why?
|
| Transcription Factor DP1 | 7 | 1998 | 136 | 0.110 |
Why?
|
| Male | 38 | 2024 | 359744 | 0.110 |
Why?
|
| Computational Biology | 2 | 2016 | 3505 | 0.110 |
Why?
|
| Gene Targeting | 2 | 2009 | 839 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 11712 | 0.110 |
Why?
|
| DNA Transposable Elements | 1 | 2017 | 756 | 0.110 |
Why?
|
| Cyclins | 3 | 2002 | 593 | 0.110 |
Why?
|
| Mosaicism | 1 | 2016 | 466 | 0.110 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2005 | 656 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2013 | 68 | 0.110 |
Why?
|
| Transfection | 10 | 2008 | 5781 | 0.110 |
Why?
|
| Protein Multimerization | 5 | 2018 | 983 | 0.110 |
Why?
|
| Sulfonamides | 5 | 2014 | 1977 | 0.100 |
Why?
|
| Androgens | 3 | 2004 | 1291 | 0.100 |
Why?
|
| Neuregulin-1 | 1 | 2013 | 135 | 0.100 |
Why?
|
| Glioma | 1 | 2007 | 3420 | 0.100 |
Why?
|
| Ovarian Neoplasms | 3 | 2020 | 4878 | 0.100 |
Why?
|
| Proteomics | 3 | 2021 | 3817 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2008 | 2506 | 0.100 |
Why?
|
| Receptor, erbB-3 | 1 | 2013 | 143 | 0.100 |
Why?
|
| Encyclopedias as Topic | 1 | 2012 | 19 | 0.100 |
Why?
|
| Metabolome | 1 | 2019 | 982 | 0.100 |
Why?
|
| DNA Mutational Analysis | 4 | 2011 | 4107 | 0.100 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2012 | 105 | 0.100 |
Why?
|
| NIH 3T3 Cells | 6 | 2013 | 670 | 0.100 |
Why?
|
| Female | 37 | 2021 | 391270 | 0.100 |
Why?
|
| Phenylthiohydantoin | 1 | 2013 | 204 | 0.100 |
Why?
|
| Antibodies | 2 | 2010 | 2421 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2004 | 3602 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2013 | 197 | 0.100 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 20080 | 0.100 |
Why?
|
| Structure-Activity Relationship | 4 | 2021 | 3084 | 0.090 |
Why?
|
| Bayes Theorem | 1 | 2019 | 2326 | 0.090 |
Why?
|
| Genes, APC | 1 | 2011 | 145 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2013 | 237 | 0.090 |
Why?
|
| Pyruvate Kinase | 1 | 2012 | 190 | 0.090 |
Why?
|
| Janus Kinases | 1 | 2012 | 250 | 0.090 |
Why?
|
| Serine Endopeptidases | 1 | 2016 | 1021 | 0.090 |
Why?
|
| Cyclin D1 | 2 | 2010 | 451 | 0.090 |
Why?
|
| Transplantation, Heterologous | 6 | 2012 | 2379 | 0.090 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2013 | 545 | 0.090 |
Why?
|
| Drug Design | 3 | 2019 | 1061 | 0.090 |
Why?
|
| Immunoconjugates | 1 | 2018 | 949 | 0.090 |
Why?
|
| DNA Primers | 7 | 2013 | 2819 | 0.090 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 326 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2005 | 1693 | 0.090 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2010 | 118 | 0.090 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2010 | 55 | 0.090 |
Why?
|
| Metabolomics | 1 | 2019 | 1628 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2021 | 65017 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 3218 | 0.090 |
Why?
|
| Benzimidazoles | 3 | 2012 | 858 | 0.090 |
Why?
|
| Adenocarcinoma | 7 | 2011 | 6315 | 0.090 |
Why?
|
| Proteome | 1 | 2020 | 1855 | 0.090 |
Why?
|
| NF-kappa B | 2 | 2013 | 2488 | 0.080 |
Why?
|
| Gene Expression Regulation | 7 | 2016 | 11903 | 0.080 |
Why?
|
| Peptides | 1 | 2021 | 4354 | 0.080 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2013 | 678 | 0.080 |
Why?
|
| Amino Acid Sequence | 8 | 2009 | 13451 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2015 | 609 | 0.080 |
Why?
|
| Doxycycline | 2 | 2009 | 341 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2017 | 1252 | 0.080 |
Why?
|
| Glycolysis | 1 | 2012 | 828 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 1741 | 0.080 |
Why?
|
| Endometrial Neoplasms | 2 | 2008 | 1357 | 0.080 |
Why?
|
| Interleukin-3 | 3 | 2005 | 425 | 0.080 |
Why?
|
| Chromosome Mapping | 4 | 2007 | 4625 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2010 | 1246 | 0.080 |
Why?
|
| Phenotype | 7 | 2016 | 16546 | 0.080 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2009 | 151 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 2105 | 0.080 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2009 | 331 | 0.080 |
Why?
|
| Cell Polarity | 2 | 2008 | 638 | 0.070 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 60 | 0.070 |
Why?
|
| Information Dissemination | 1 | 2016 | 1131 | 0.070 |
Why?
|
| Liposarcoma | 1 | 2010 | 283 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2013 | 4573 | 0.070 |
Why?
|
| Indoles | 2 | 2013 | 1829 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2000 | 5125 | 0.070 |
Why?
|
| Molecular Structure | 3 | 2021 | 1895 | 0.070 |
Why?
|
| In Situ Hybridization | 3 | 2010 | 1900 | 0.070 |
Why?
|
| Molecular Weight | 1 | 2009 | 2186 | 0.070 |
Why?
|
| Macaca fascicularis | 2 | 2020 | 900 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 6498 | 0.070 |
Why?
|
| Mass Spectrometry | 3 | 2021 | 2192 | 0.070 |
Why?
|
| Precipitin Tests | 3 | 2005 | 814 | 0.070 |
Why?
|
| Pyridones | 1 | 2012 | 792 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2008 | 435 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2010 | 719 | 0.070 |
Why?
|
| Genotype | 6 | 2009 | 12960 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 3 | 2003 | 1612 | 0.070 |
Why?
|
| Point Mutation | 1 | 2011 | 1594 | 0.070 |
Why?
|
| Lentivirus | 1 | 2009 | 506 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2009 | 943 | 0.060 |
Why?
|
| Saposins | 1 | 2005 | 26 | 0.060 |
Why?
|
| Quinolines | 1 | 2011 | 759 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2002 | 2913 | 0.060 |
Why?
|
| Piperazines | 2 | 2015 | 2525 | 0.060 |
Why?
|
| Kinetics | 3 | 2022 | 6377 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2000 | 1077 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2005 | 2418 | 0.060 |
Why?
|
| E2F1 Transcription Factor | 5 | 1996 | 178 | 0.060 |
Why?
|
| Homozygote | 3 | 2005 | 1788 | 0.060 |
Why?
|
| Pyridines | 2 | 2015 | 2879 | 0.060 |
Why?
|
| Probability | 2 | 2007 | 2475 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2010 | 679 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 635 | 0.060 |
Why?
|
| Oncogene Proteins | 2 | 2006 | 719 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2011 | 933 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 3484 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 1763 | 0.060 |
Why?
|
| Sequence Deletion | 4 | 2006 | 1493 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 2 | 2006 | 877 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 20 | 2 | 2002 | 127 | 0.060 |
Why?
|
| Enzyme Inhibitors | 4 | 2020 | 3726 | 0.060 |
Why?
|
| Amino Acid Substitution | 3 | 2011 | 1737 | 0.060 |
Why?
|
| Haplotypes | 3 | 2006 | 2764 | 0.060 |
Why?
|
| Glioblastoma | 4 | 2019 | 3484 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 1547 | 0.060 |
Why?
|
| Gene Expression | 2 | 2015 | 7588 | 0.060 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2015 | 1724 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2021 | 10827 | 0.060 |
Why?
|
| Cell Growth Processes | 3 | 2010 | 384 | 0.060 |
Why?
|
| Noonan Syndrome | 1 | 2004 | 120 | 0.060 |
Why?
|
| Cluster Analysis | 3 | 2008 | 2698 | 0.060 |
Why?
|
| Homeostasis | 2 | 2013 | 3306 | 0.060 |
Why?
|
| Mice, Inbred NOD | 3 | 2014 | 1837 | 0.060 |
Why?
|
| Thrombocythemia, Essential | 1 | 2005 | 107 | 0.060 |
Why?
|
| Hydrogen Bonding | 1 | 2004 | 291 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2008 | 276 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2012 | 8035 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 8056 | 0.060 |
Why?
|
| Cells, Cultured | 8 | 2016 | 18957 | 0.060 |
Why?
|
| Polycythemia Vera | 1 | 2005 | 160 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 1553 | 0.050 |
Why?
|
| Binding Sites | 8 | 2012 | 6048 | 0.050 |
Why?
|
| Mutagenesis | 3 | 2013 | 1234 | 0.050 |
Why?
|
| Ligands | 1 | 2010 | 3276 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2004 | 621 | 0.050 |
Why?
|
| Microarray Analysis | 3 | 2013 | 747 | 0.050 |
Why?
|
| Genes, Homeobox | 1 | 2004 | 284 | 0.050 |
Why?
|
| Species Specificity | 1 | 2007 | 2418 | 0.050 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2003 | 101 | 0.050 |
Why?
|
| Microcephaly | 1 | 2007 | 425 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 613 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2019 | 3790 | 0.050 |
Why?
|
| Epidermal Growth Factor | 2 | 2005 | 695 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 1 | 2005 | 416 | 0.050 |
Why?
|
| Primary Myelofibrosis | 1 | 2005 | 210 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 1245 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2004 | 9530 | 0.050 |
Why?
|
| Patient Selection | 1 | 2015 | 4283 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2011 | 1690 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 459 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 3 | 2015 | 2005 | 0.050 |
Why?
|
| Genes, p53 | 2 | 2008 | 713 | 0.050 |
Why?
|
| S Phase | 3 | 2000 | 422 | 0.050 |
Why?
|
| Cell Nucleus | 4 | 2008 | 2907 | 0.050 |
Why?
|
| Nucleoside-Phosphate Kinase | 1 | 2001 | 25 | 0.050 |
Why?
|
| Sirolimus | 3 | 2004 | 1547 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2010 | 1407 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2005 | 580 | 0.050 |
Why?
|
| Chromatin | 1 | 2013 | 2938 | 0.050 |
Why?
|
| Kidney | 3 | 2013 | 7064 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2008 | 3094 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2007 | 979 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2004 | 507 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2004 | 11071 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 13308 | 0.050 |
Why?
|
| Cloning, Molecular | 5 | 2013 | 4169 | 0.050 |
Why?
|
| Vitamin D | 2 | 2013 | 3291 | 0.050 |
Why?
|
| Administration, Oral | 3 | 2016 | 4035 | 0.050 |
Why?
|
| Tumor Burden | 3 | 2012 | 1895 | 0.050 |
Why?
|
| Cell Communication | 1 | 2008 | 1653 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 2013 | 0.050 |
Why?
|
| Genetic Variation | 4 | 2013 | 6551 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2008 | 2696 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2011 | 2560 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2004 | 495 | 0.040 |
Why?
|
| Indazoles | 2 | 2012 | 302 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2014 | 1728 | 0.040 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 384 | 0.040 |
Why?
|
| Paraffin | 1 | 1999 | 37 | 0.040 |
Why?
|
| Tissue Embedding | 1 | 1999 | 42 | 0.040 |
Why?
|
| Transgenes | 1 | 2003 | 1006 | 0.040 |
Why?
|
| Time Factors | 3 | 2018 | 40165 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2005 | 2295 | 0.040 |
Why?
|
| Placebos | 1 | 2004 | 1668 | 0.040 |
Why?
|
| Half-Life | 1 | 2000 | 652 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2008 | 1304 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 4 | 2016 | 22023 | 0.040 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2000 | 186 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2016 | 1982 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2012 | 256 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 854 | 0.040 |
Why?
|
| Sarcoma | 1 | 2010 | 1786 | 0.040 |
Why?
|
| DNA | 6 | 2015 | 7233 | 0.040 |
Why?
|
| Neoplasms, Experimental | 3 | 2010 | 1229 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 2001 | 666 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2002 | 1084 | 0.040 |
Why?
|
| Sensitivity and Specificity | 4 | 2008 | 14660 | 0.040 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 1998 | 73 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2009 | 115 | 0.040 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2018 | 114 | 0.040 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 1998 | 71 | 0.040 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 1999 | 114 | 0.040 |
Why?
|
| Aspartic Acid | 1 | 2000 | 576 | 0.040 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 6538 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 479 | 0.040 |
Why?
|
| Algorithms | 3 | 2008 | 13981 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2019 | 267 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2004 | 1403 | 0.040 |
Why?
|
| Aged | 11 | 2019 | 169152 | 0.040 |
Why?
|
| Chromosomes, Human | 2 | 2012 | 442 | 0.040 |
Why?
|
| Genetic Drift | 1 | 2017 | 41 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2013 | 17790 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2006 | 3735 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2003 | 1166 | 0.030 |
Why?
|
| RNA Polymerase I | 1 | 1996 | 22 | 0.030 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 2717 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2018 | 356 | 0.030 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 1996 | 110 | 0.030 |
Why?
|
| Prognosis | 4 | 2008 | 29658 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 1343 | 0.030 |
Why?
|
| Breast | 2 | 2004 | 1963 | 0.030 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2016 | 68 | 0.030 |
Why?
|
| Mice, Knockout | 4 | 2017 | 14372 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2006 | 3682 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 4357 | 0.030 |
Why?
|
| Biological Transport | 1 | 2000 | 2086 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 715 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 5799 | 0.030 |
Why?
|
| Karyotyping | 2 | 2008 | 1171 | 0.030 |
Why?
|
| Cell Line, Transformed | 2 | 2011 | 869 | 0.030 |
Why?
|
| RNA | 2 | 2003 | 2722 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 2299 | 0.030 |
Why?
|
| Middle Aged | 11 | 2019 | 220352 | 0.030 |
Why?
|
| Dogs | 1 | 2020 | 3841 | 0.030 |
Why?
|
| Cell Separation | 2 | 2000 | 1720 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2015 | 189 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 9276 | 0.030 |
Why?
|
| Adult | 12 | 2016 | 219994 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2015 | 140 | 0.030 |
Why?
|
| Protein Stability | 1 | 2016 | 566 | 0.030 |
Why?
|
| Sulfones | 1 | 2017 | 447 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 4291 | 0.030 |
Why?
|
| Multigene Family | 2 | 2010 | 1077 | 0.030 |
Why?
|
| Trypan Blue | 1 | 2013 | 22 | 0.030 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2013 | 39 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2014 | 85 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 161 | 0.030 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2013 | 57 | 0.030 |
Why?
|
| Databases, Genetic | 2 | 2016 | 1738 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 453 | 0.030 |
Why?
|
| Mitosis | 2 | 2012 | 1191 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 1135 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 2013 | 366 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 6216 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 452 | 0.030 |
Why?
|
| Phosphoenolpyruvate | 1 | 2012 | 16 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2014 | 245 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2016 | 1229 | 0.030 |
Why?
|
| Guanylate Cyclase | 1 | 2013 | 205 | 0.030 |
Why?
|
| Tail | 1 | 2013 | 92 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2014 | 265 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2012 | 297 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2003 | 2640 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 1296 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2015 | 419 | 0.030 |
Why?
|
| Amino Acid Motifs | 2 | 2006 | 929 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2013 | 159 | 0.030 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2012 | 19 | 0.030 |
Why?
|
| Acetamides | 1 | 2014 | 256 | 0.030 |
Why?
|
| Subcutaneous Tissue | 1 | 2013 | 132 | 0.030 |
Why?
|
| Aged, 80 and over | 5 | 2006 | 58995 | 0.030 |
Why?
|
| Ions | 1 | 2013 | 261 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 1996 | 537 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 5130 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 622 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2005 | 458 | 0.030 |
Why?
|
| Carbon Isotopes | 1 | 2012 | 459 | 0.020 |
Why?
|
| Acyltransferases | 1 | 2013 | 305 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 378 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2015 | 588 | 0.020 |
Why?
|
| Exons | 3 | 2005 | 2388 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2011 | 190 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2015 | 1991 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 476 | 0.020 |
Why?
|
| Acetyltransferases | 2 | 2004 | 231 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2000 | 1841 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 361 | 0.020 |
Why?
|
| Minerals | 1 | 2013 | 283 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2014 | 384 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 6828 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 264 | 0.020 |
Why?
|
| Growth Plate | 1 | 2013 | 274 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 4166 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 1854 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2010 | 4122 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 395 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2011 | 126 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 877 | 0.020 |
Why?
|
| Sex Factors | 1 | 2005 | 10547 | 0.020 |
Why?
|
| Models, Genetic | 3 | 2006 | 3442 | 0.020 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2010 | 41 | 0.020 |
Why?
|
| Histone Acetyltransferases | 2 | 2004 | 337 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2006 | 3426 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2016 | 1674 | 0.020 |
Why?
|
| Wnt1 Protein | 1 | 2010 | 120 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2010 | 203 | 0.020 |
Why?
|
| Amino Acids | 1 | 2016 | 1714 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 730 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2008 | 11152 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2010 | 1928 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2014 | 1754 | 0.020 |
Why?
|
| Bone Development | 1 | 2013 | 472 | 0.020 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2012 | 220 | 0.020 |
Why?
|
| Cytokines | 1 | 2004 | 7343 | 0.020 |
Why?
|
| Luciferases | 2 | 2005 | 716 | 0.020 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 633 | 0.020 |
Why?
|
| Conserved Sequence | 2 | 2007 | 1167 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1652 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2010 | 526 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2013 | 743 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 829 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2014 | 1069 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2012 | 591 | 0.020 |
Why?
|
| Tubulin | 1 | 2012 | 692 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 956 | 0.020 |
Why?
|
| Telomerase | 2 | 2004 | 746 | 0.020 |
Why?
|
| Adenine | 1 | 2013 | 975 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 2101 | 0.020 |
Why?
|
| Biological Evolution | 1 | 1994 | 1074 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 858 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 473 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 680 | 0.020 |
Why?
|
| Prevalence | 1 | 2005 | 15687 | 0.020 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 2526 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2008 | 310 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2010 | 503 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2012 | 1134 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 1504 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2010 | 814 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 373 | 0.020 |
Why?
|
| Insulin | 1 | 2002 | 6597 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 1697 | 0.020 |
Why?
|
| Nuclear Export Signals | 1 | 2006 | 9 | 0.020 |
Why?
|
| Tyrosine | 1 | 2011 | 1438 | 0.020 |
Why?
|
| Survival Rate | 2 | 2013 | 12808 | 0.020 |
Why?
|
| Psychomotor Disorders | 1 | 2007 | 149 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 551 | 0.020 |
Why?
|
| Femur | 1 | 2013 | 1302 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 4024 | 0.020 |
Why?
|
| Nuclear Localization Signals | 1 | 2006 | 77 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 1189 | 0.020 |
Why?
|
| Risk Factors | 2 | 2005 | 74359 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1997 | 5870 | 0.020 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2005 | 46 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 769 | 0.020 |
Why?
|
| Dictyostelium | 1 | 2006 | 70 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 15289 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2006 | 150 | 0.020 |
Why?
|
| SH2 Domain-Containing Protein Tyrosine Phosphatases | 1 | 2004 | 43 | 0.020 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2006 | 202 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1705 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2006 | 428 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2005 | 162 | 0.020 |
Why?
|
| Restriction Mapping | 2 | 1996 | 852 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2006 | 162 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2006 | 256 | 0.020 |
Why?
|
| Cells | 1 | 2006 | 164 | 0.020 |
Why?
|
| Osteosarcoma | 2 | 2005 | 897 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 749 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2004 | 46 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 2057 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2006 | 599 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 4899 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2006 | 330 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 1442 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2005 | 575 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2005 | 700 | 0.010 |
Why?
|
| Hepatitis B, Chronic | 1 | 2008 | 403 | 0.010 |
Why?
|
| Oligodendroglioma | 1 | 2005 | 279 | 0.010 |
Why?
|
| src Homology Domains | 1 | 2004 | 361 | 0.010 |
Why?
|
| Genes, Neoplasm | 1 | 2005 | 370 | 0.010 |
Why?
|
| Phosphoglycerate Kinase | 1 | 2003 | 67 | 0.010 |
Why?
|
| Acetylation | 1 | 2006 | 1062 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 4407 | 0.010 |
Why?
|
| Cellular Apoptosis Susceptibility Protein | 1 | 2002 | 5 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 186 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2003 | 127 | 0.010 |
Why?
|
| Urothelium | 1 | 2005 | 277 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2013 | 4090 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 2006 | 424 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2006 | 835 | 0.010 |
Why?
|
| Karyopherins | 1 | 2003 | 130 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2003 | 203 | 0.010 |
Why?
|
| Granulocytes | 1 | 2005 | 551 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2015 | 3562 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2005 | 565 | 0.010 |
Why?
|
| Calmodulin | 1 | 2003 | 217 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2002 | 260 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 2004 | 271 | 0.010 |
Why?
|
| Body Fluids | 1 | 2004 | 319 | 0.010 |
Why?
|
| Benzothiazoles | 1 | 2003 | 246 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2005 | 595 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 421 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2004 | 410 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 3765 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2004 | 452 | 0.010 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2003 | 89 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 426 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2004 | 454 | 0.010 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 1 | 2002 | 104 | 0.010 |
Why?
|
| Body Weight | 1 | 2013 | 4611 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2009 | 3615 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2007 | 1187 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2002 | 532 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2005 | 1529 | 0.010 |
Why?
|
| Genes, abl | 1 | 2000 | 69 | 0.010 |
Why?
|
| Chromones | 1 | 2000 | 149 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2000 | 189 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2000 | 343 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 2000 | 148 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2003 | 482 | 0.010 |
Why?
|
| Child | 3 | 2016 | 79806 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 924 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2005 | 1526 | 0.010 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 1031 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 2471 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 5761 | 0.010 |
Why?
|
| Protozoan Proteins | 1 | 2006 | 839 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 1998 | 0.010 |
Why?
|
| Japan | 1 | 2004 | 1369 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 3105 | 0.010 |
Why?
|
| Epithelium | 1 | 2004 | 1605 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 2176 | 0.010 |
Why?
|
| Ubiquitins | 1 | 2000 | 370 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2002 | 1753 | 0.010 |
Why?
|
| Astrocytes | 1 | 2006 | 1338 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 2651 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2004 | 796 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 4902 | 0.010 |
Why?
|
| Heterozygote | 1 | 2005 | 2798 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2004 | 1513 | 0.010 |
Why?
|
| Pancreas | 1 | 2004 | 1677 | 0.010 |
Why?
|
| Neurons | 1 | 2016 | 9426 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 3106 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2004 | 1096 | 0.010 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1997 | 222 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 1996 | 183 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1999 | 1433 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 3618 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1997 | 461 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 1529 | 0.010 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1994 | 31 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1995 | 221 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1995 | 418 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 2917 | 0.010 |
Why?
|
| Adolescent | 2 | 2016 | 87810 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 2529 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1994 | 262 | 0.010 |
Why?
|
| Introns | 1 | 1996 | 978 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 42063 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 1994 | 291 | 0.010 |
Why?
|
| E1A-Associated p300 Protein | 1 | 1994 | 123 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 1992 | 30 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3826 | 0.010 |
Why?
|
| Stem Cells | 1 | 2005 | 3523 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 5206 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 1994 | 255 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1992 | 1142 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 9185 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2004 | 3531 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 12626 | 0.010 |
Why?
|
| Plasmids | 1 | 1995 | 2275 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 58741 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 2753 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 5075 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 80372 | 0.000 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1994 | 1356 | 0.000 |
Why?
|
| Lung | 1 | 2004 | 9994 | 0.000 |
Why?
|
| Pregnancy | 1 | 2004 | 29749 | 0.000 |
Why?
|
| Bone Neoplasms | 1 | 1995 | 2532 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 7408 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2003 | 24123 | 0.000 |
Why?
|
| Brain | 1 | 2007 | 26951 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 36290 | 0.000 |
Why?
|
| United States | 1 | 2004 | 72461 | 0.000 |
Why?
|